Pediatric Cancer: The Issues

Cancer is the leading cause of disease-related death for kids under 15 in the U.S., but pediatric cancer research is vastly underfunded by the federal government and mostly ignored in pharmaceutical research. We need to do more for kids like Jonny.

Pediatric Cancer is Extremely Underfunded

The National Cancer Institute allots only 4 percent of its budget for pediatric cancer research, and funding for other pediatric diseases is also scarce. 

Pediatric Cancer Treatments Aren’t a Focus

Since 1990, fewer than 10 drugs have been developed to treat pediatric cancer, compared to more than 200 for adults.

Federal Cancer Funding Has Stagnated in General

With the exception of the one-time increase allocated in the American Recovery and Reinvestment Act, federal investment in cancer research hasn’t increased since 2003.

The Rate of Pediatric Cancer is Climbing

The incidence of pediatric cancer has risen about 1 percent annually for the past 35 years.

Pediatric Cancer Doesn’t End with Childhood

At age 40, survivors of pediatric cancer are twice as likely as the general population to develop a second cancer.

The Least Amount of Hope is for the Youngest

The five-year survival rate for infants with cancer remains lower than that of pediatric cancer patients age 1-14.

Pediatric Cancer is Overwhelmingly Genetic

Most pediatric cancers are the result of DNA changes early in life, even before birth. They’re only rarely linked to environmental risk factors.

Research Saves Lives – When It Can Be Funded

Thanks to advancements from pediatric cancer research and participation in clinical trials, the mortality rate for some pediatric cancers has decreased by more than 50 percent since 1981.

Dedicated to the life of Jonny Wade.